Funds · GSK

Who owns GSK?

Institutional ownership of GSK plc from Form 13F, Q2 2026

1,036 institutional managers reported holding GSK plc (GSK) in Form 13F filings for Q2 2026, with 346,709,884 shares worth $18.2B. The largest reported holder was FMR LLC. Managers that filed both quarters cut a net 27,869,894 shares (-7.5%). 94 opened new positions and 81 sold out.

Funds holding
1,036
Value held
$18.2B
New / sold out
94 / 81
Net shares, same filers
-7.5%

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Largest holders of GSK

FundValueShare of 13F holdingsSharesMove
FMR LLC$3.4B18.7%64,961,641Trimmed
Dodge & Cox$2.5B13.9%48,197,514Trimmed
Fisher Asset Management, LLC$1.9B10.3%35,722,792Added
Primecap Management Co$1.3B7.3%25,182,068Unchanged
Wellington Management Group LLP$597M3.3%11,396,249Trimmed
JTC Employer Solutions Trustee Ltd$450M2.5%8,592,987Trimmed
Morgan Stanley$401M2.2%7,657,562Trimmed
Royal Bank of Canada$398M2.2%7,588,928Added
Price T Rowe Associates Inc$363M2.0%6,923,642Trimmed
Acadian Asset Management LLC$349M1.9%6,660,434Trimmed
Goldman Sachs Group Inc$334M1.8%6,371,442Trimmed
State Street Corp$315M1.7%5,959,115Trimmed
Mondrian Investment Partners LTD$257M1.4%4,910,830Trimmed
Bank of Montreal$212M1.2%4,042,863Trimmed
BlackRock, Inc.$190M1.0%3,620,294Added
Grantham, Mayo, Van Otterloo & Co. LLC$189M1.0%3,599,521Added
Hotchkis & Wiley Capital Management LLC$179M1.0%3,413,574Trimmed
Equity Investment Corp$171M0.9%3,269,765Added
UBS Group AG$147M0.8%2,806,205Added
Connor, Clark & Lunn Investment Management Ltd.$145M0.8%2,767,591Trimmed
Dimensional Fund Advisors LP$141M0.8%2,691,698Added
Point72 Asset Management, L.P.$139M0.8%2,652,881New
Bank of America Corp$116M0.6%2,216,888Added
JPMorgan Chase & Co$110M0.6%2,085,014Added
Envestnet Asset Management Inc$100M0.6%1,908,549Added

Share of 13F holdings is each fund's shares as a share of the 346,709,884 GSK shares all 13F filers reported, not of shares outstanding.

Biggest buyers in Q2 2026

  1. Point72 Asset Management, L.P. New+$139M
  2. JPMorgan Chase & Co Added+$79.5M
  3. Fisher Asset Management, LLC Added+$62.9M
  4. D. E. Shaw & Co., Inc. New+$53.4M
  5. NewEdge Advisors, LLC New+$50.0M
  6. UBS Group AG Added+$37.8M
  7. Qube Research & Technologies Ltd Added+$27.8M
  8. Life Cycle Investment Partners Ltd New+$27.8M
  9. Capricorn Fund Managers Ltd New+$22.4M
  10. BI Asset Management Fondsmaeglerselskab A/S Added+$16.0M

Biggest sellers in Q2 2026

  1. Dodge & Cox Trimmed-$549M
  2. Holocene Advisors, LP Sold out-$305M
  3. Acadian Asset Management LLC Trimmed-$269M
  4. Morgan Stanley Trimmed-$177M
  5. Goldman Sachs Group Inc Trimmed-$169M
  6. FMR LLC Trimmed-$142M
  7. Eversept Partners, LP Trimmed-$68.3M
  8. Alyeska Investment Group, L.P. Sold out-$66.8M
  9. Citigroup Inc Trimmed-$60.4M
  10. Sei Investments Co Trimmed-$54.3M

The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $847M and sold $2.3B; 359 added and 326 trimmed.

Schedule 13D and 13G filings on GSK

Owners of more than 5% must file within days, so these can be newer than the 13F data.

Questions about GSK ownership

Who owns GSK stock?
1,036 institutional investment managers reported GSK positions in their Form 13F filings for Q2 2026, holding 346,709,884 shares worth $18.2B in total. FMR LLC reported the largest position.
Are funds buying or selling GSK?
In Q2 2026, 94 managers opened new GSK positions, 359 added, 326 trimmed and 81 sold out. Managers that filed in both quarters sold a net 27,869,894 shares.
How current is this GSK institutional ownership data?
It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to GSK by CUSIP. Options are left out. GSK news and filings · GSK insider trades · Top funds